**References 31s – 71s**

31s. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015*.* MMWR Recomm Rep2015;64(Rr-03):1-137.

32s. Lewis RM, Laprise JF, Gargano JW, et al. Estimated prevalence and incidence of disease-associated HPV types among 15-59-year-olds in the United States. Sex Transm Dis2021.

33s. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and cost-effectiveness of HPV vaccination through age 45 years in the United States. Ann Intern Med 2020;172:22-29.

34s. Laprise JF, Markowitz LE, Chesson HW, et al. Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: A cost-effectiveness analysis. J Infect Dis 2016;214:685-688.

35s. Chesson HW, Laprise JF, Brisson M, et al. Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine. J Infect Dis 2016;213:1694-1700.

36s. Brisson M. Cost-effectiveness of extending HPV vaccination above age 26 years in the United States. Meeting of the Advisory Committee on Immunization Practices; February, 2019. Atlanta.

37s. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014. MMWR Morb Mortal Wkly Rep 2014;63:620-624.

38s. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2014. MMWR Morb Mortal Wkly Rep 2015;64:784-792.

39s. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65:850-858.

40s. Walker TY, Elam-Evans LD, Singleton JA, et al. national, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016. MMWR Morb Mortal Wkly Rep 2017;66:874-882.

41s. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine2010;28:6858-6867.

42s. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ2009;339:b3884.

43s. Chesson HW, Meites E, Ekwueme DU, et al. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States. Vaccine2018;36:4362-4368.

44s. Chesson HW, Meites E, Ekwueme DU, et al. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model. Vaccine2020;38(50):8032-8039.

45s. Henk HJ, Insinga RP, Singhal PK, et al. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis 2010;14:29-36.

46s. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-120.

47s. Hoy T, Singhal PK, Willey VJ, et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009;25:2343-2351.

48s. Dahlstrom KR, Fu S, Chan W, et al. Medical care costs associated with genital warts for commercially insured US patients. Pharmacoeconomics 2018;36:1355-1365.

49s. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-615.

50s. Insinga RP, Ye X, Singhal PK, et al. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan. Gynecol Oncol 2008;111:188-196.

51s. Sher DJ, Fidler MJ, Tishler RB, et al. Cost-effectiveness analysis of chemoradiation therapy versus transoral robotic surgery for human papillomavirus-associated, clinical N2 oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2016;94:512-522.

52s. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008;198:500.e501-500.e507.

53s. Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011;29:8443-8450.

54s. Burger EA, de Kok I, Groene E, et al. Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis. J Natl Cancer Inst2020;112(9):955-963.

55s. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis2009;199(6):805-814.

56s. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011;20(2):287-296.

57s. Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers - United States, 2008-2012. MMWR Morb Mortal Wkly Rep 2016;65(26):661-666.

58s. Drolet M, Laprise JF, Brotherton JML, et al. The impact of human papillomavirus catch-up vaccination in Australia: Implications for introduction of multiple age cohort vaccination and postvaccination data interpretation. J Infect Dis2017;216(10):1205-1209.

59s. Novakovic D, Cheng ATL, Zurynski Y, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis2018;217(2):208-212.

60s. Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill2018;23(41).

61s. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep2019;68(32):698-702.

62s. Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004;36:11-19.

63s. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep*.* 2007;56(RR-2):1-24.

64s. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis2007;13(1):28-41.

65s. Tuite AR, Burchell AN, Fisman DN. Cost-effectiveness of enhanced syphilis screening among HIV-positive men who have sex with men: a microsimulation model. PLoS One2014;9(7):e101240.

66s. Williams AM, Gift TL, OʼDonnell LN, et al. Assessment of the cost-effectiveness of a brief video intervention for sexually transmitted disease prevention. Sex Transm Dis2020;47(2):130-135.

67s. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med2009;151(8):538-545.

68s. Goldhaber-Fiebert JD, Stout NK, Salomon JA, et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst2008;100(5):308-320.

69s. Kim JJ, Campos NG, Sy S, et al. Inefficiencies and high-value improvements in U.S. cervical cancer screening practice: a cost-effectiveness analysis. Ann Intern Med2015;163(8):589-597.

70s. Spencer JC, Brewer NT, Trogdon JG, et al. Cost-effectiveness of interventions to increase HPV vaccine uptake. Pediatrics2020;146(6).

71s. Chesson HW, Ekwueme DU, Saraiya M, et al. The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States. Sex Transm Dis2014;41(11):656-659.